您的购物车当前为空
Lorukafusp alfa(14.18 mAb; hu14.18-IL2)是一种由人源化14.18抗GD2抗体和IL210连接而成的免疫细胞因子。该化合物通过其hu14.18-IL2与肿瘤细胞表面的GD2结合,激活抗体依赖性细胞毒性(ADCC)和补体依赖性细胞毒性,以及与效应细胞上Fc受体结合并激活NK和T细胞的活性,从而显现出抗肿瘤效果。
别名 hu14.18-IL2, EMD 273063, 14.18 mAb
Lorukafusp alfa(14.18 mAb; hu14.18-IL2)是一种由人源化14.18抗GD2抗体和IL210连接而成的免疫细胞因子。该化合物通过其hu14.18-IL2与肿瘤细胞表面的GD2结合,激活抗体依赖性细胞毒性(ADCC)和补体依赖性细胞毒性,以及与效应细胞上Fc受体结合并激活NK和T细胞的活性,从而显现出抗肿瘤效果。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | 待询 | 待询 | |
| 5 mg | 待询 | 待询 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
凭借在化合物合成方面的丰富经验,我们可以根据您的研究需求为该产品提供快速定制合成服务。
| 产品描述 | Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine composed of the humanized 14.18 anti-GD2 monoclonal antibody (mAb) connected to interleukin-2 (IL210). It exerts its anti-tumor effects [1] through the induction of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity. This is achieved by the targeted binding of hu14.18-IL2 to GD2-expressing tumor cells, which facilitates subsequent interaction with Fc receptors on immune effector cells, as well as the stimulation of natural killer (NK) and T cells through their IL2 receptors. |
| 别名 | hu14.18-IL2, EMD 273063, 14.18 mAb |
| 反应种属 | Human |
| 应用 | ELISAFACSFunctional assay |
| 抗体种类 | Monoclonal |
| 缓冲液 | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| 内毒素 | <1.0 EU/mg |
| 偶联 | Unconjugated |
| 靶点 | GD2/IL-2R |
| CAS No. | 2131168-99-3 |
| 存储 | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 |
对于不同动物的给药剂量换算,您也可以参考 更多